entertainment -WSS

entertainment

author：hotspot 2025-09-29 13:46:13 - browse：63466

Illustration of researchers working among oversized pill bottles, lab equipment, and medicine for story about the development of obesity medications – health and pharma coverage from STAT — Molly Ferguson for STAT

The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to develop their own obesity treatments, with most of them trying to emulate the same approach as the blockbuster products.

Nearly 70 obesity treatments are in development, and about two-thirds use a similar mechanism as Wegovy and Mounjaro, according to the STAT Obesity Drug Tracker, a new database compiled by STAT. There are also a minority of companies pursuing entirely different approaches, hoping that they will stand out among the field.

The tracker, which will be updated with significant developments each quarter, gives a sense of what new mechanisms could hit the market, how they would be delivered, and which companies are running the most trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Why Eli Lilly’s earnings didn’t quite live up to the hype

entertainment

WSS

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Telehealth for opioid use disorder is lifesaving

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Congress might make insulin pumps more accessible to the blind

Diverse clinical trials: Why aren’t we there yet?

New weight loss drugs vying to be the next Wegovy or Mounjaro

leisure time

entertainment

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

Ebola vaccine can save some who are already sick, per new study

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Telehealth for opioid use disorder is lifesaving

Supreme Court strikes down use of affirmative action

STAT Boddities: What happens to the brain when we get scared?

Wildfire smoke exposes gaps in outdoor worker protections

Diverse clinical trials: Why aren’t we there yet?

Apple is now the first public company to be valued at $3 trillion

FDA approves updated Covid vaccines

focus

WATCH: Why do bright lights make us see spots?

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Artificial intelligence use in health care faces greater scrutiny in 2024

How medical schools plan to diversify without affirmative action

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Regeneron agrees to White House price limits on anti

entertainment

hotspot

hotspot

focus